Literature DB >> 2159544

Induction of protective immunity in animals vaccinated with recombinant vaccinia viruses that express PreM and E glycoproteins of Japanese encephalitis virus.

A Yasuda1, J Kimura-Kuroda, M Ogimoto, M Miyamoto, T Sata, T Sato, C Takamura, T Kurata, A Kojima, K Yasui.   

Abstract

A cDNA clone representing the genome of structural proteins of Japanese encephalitis virus (JEV) was inserted into the thymidine kinase gene of vaccinia virus strains LC16mO and WR under the control of a strong early-late promoter for the vaccinia virus 7.5-kilodalton polypeptide. Indirect immunofluorescence and fluorescence-activated flow cytometric analysis revealed that the recombinant vaccinia viruses expressed JEV E protein on the membrane surface, as well as in the cytoplasm, of recombinant-infected cells. In addition, the E protein expressed from the JEV recombinants reacted to nine different characteristic monoclonal antibodies, some of which have hemagglutination-inhibiting and JEV-neutralizing activities. Radioimmunoprecipitation analysis demonstrated that two major proteins expressed in recombinant-infected cells were processed and glycosylated as the authentic PreM and E glycoproteins of JEV. Inoculation of rabbits with the infectious recombinant vaccinia virus resulted in rapid production of antiserum specific for the PreM and E glycoproteins of JEV. This antiserum had both hemagglutination-inhibiting and virus-neutralizing activities against JEV. Furthermore, mice vaccinated with the recombinant also produced JEV-neutralizing antibodies and were resistant to challenge with JEV.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2159544      PMCID: PMC249459          DOI: 10.1128/JVI.64.6.2788-2795.1990

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

1.  THE INTERACTION OF JAPANESE ENCEPHALITIS VIRUS WITH ITS RECEPTOR PREPARED FROM PIGEON RED BLOOD CELLS AND SUSCEPTIBLE CELLS.

Authors:  H MORI; H NAKAI; T NOZIMA
Journal:  Acta Virol       Date:  1965-03       Impact factor: 1.162

2.  Improved recombinant LC16m0 or LC16m8 vaccinia virus successfully expressing hepatitis B surface antigen.

Authors:  K Watanabe; H Kobayashi; K Kajiyama; M Morita; A Yasuda; H Gotoh; S Saeki; M Sugimoto; H Saito; A Kojima
Journal:  Vaccine       Date:  1989-02       Impact factor: 3.641

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Topographical analysis of antigenic determinants on envelope glycoprotein V3 (E) of Japanese encephalitis virus, using monoclonal antibodies.

Authors:  J Kimura-Kuroda; K Yasui
Journal:  J Virol       Date:  1983-01       Impact factor: 5.103

5.  Antigenic characterization of flavivirus structural proteins separated by isoelectric focusing.

Authors:  D W Trent
Journal:  J Virol       Date:  1977-06       Impact factor: 5.103

6.  A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity.

Authors:  A P Feinberg; B Vogelstein
Journal:  Anal Biochem       Date:  1983-07-01       Impact factor: 3.365

7.  Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen.

Authors:  G L Smith; M Mackett; B Moss
Journal:  Nature       Date:  1983-04-07       Impact factor: 49.962

8.  Construction of live vaccines using genetically engineered poxviruses: biological activity of vaccinia virus recombinants expressing the hepatitis B virus surface antigen and the herpes simplex virus glycoprotein D.

Authors:  E Paoletti; B R Lipinskas; C Samsonoff; S Mercer; D Panicali
Journal:  Proc Natl Acad Sci U S A       Date:  1984-01       Impact factor: 11.205

9.  Mice immunized with recombinant vaccinia virus expressing dengue 4 virus structural proteins with or without nonstructural protein NS1 are protected against fatal dengue virus encephalitis.

Authors:  M Bray; B T Zhao; L Markoff; K H Eckels; R M Chanock; C J Lai
Journal:  J Virol       Date:  1989-06       Impact factor: 5.103

10.  Characterization of Japanese encephalitis virus envelope protein expressed by recombinant baculoviruses.

Authors:  Y Matsuura; M Miyamoto; T Sato; C Morita; K Yasui
Journal:  Virology       Date:  1989-12       Impact factor: 3.616

View more
  27 in total

1.  Construction and characterization of chimeric tick-borne encephalitis/dengue type 4 viruses.

Authors:  A G Pletnev; M Bray; J Huggins; C J Lai
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

2.  An attenuated LC16m8 smallpox vaccine: analysis of full-genome sequence and induction of immune protection.

Authors:  Shigeru Morikawa; Tokuki Sakiyama; Hideki Hasegawa; Masayuki Saijo; Akihiko Maeda; Ichiro Kurane; Go Maeno; Junko Kimura; Chie Hirama; Teruhiko Yoshida; Yasuko Asahi-Ozaki; Tetsutaro Sata; Takeshi Kurata; Asato Kojima
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

3.  Flavivirus premembrane protein cleavage and spike heterodimer secretion require the function of the viral proteinase NS3.

Authors:  M Lobigs
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

4.  Degradation of Japanese encephalitis virus by neutrophils.

Authors:  S Srivastava; N Khanna; S K Saxena; A Singh; A Mathur; T N Dhole
Journal:  Int J Exp Pathol       Date:  1999-02       Impact factor: 1.925

5.  NS2B-3 proteinase-mediated processing in the yellow fever virus structural region: in vitro and in vivo studies.

Authors:  S M Amberg; A Nestorowicz; D W McCourt; C M Rice
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

6.  Nucleotide sequence and mutation rate of the H strain of hepatitis C virus.

Authors:  N Ogata; H J Alter; R H Miller; R H Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

7.  Expression and characterization of bovine lactoperoxidase by recombinant vaccinia virus.

Authors:  Tetsuya Tanaka; Xuenan Xuan; Asato Kojima; Ikuo Igarashi; Kozo Fujisaki; Kei-Ichi Shimazaki
Journal:  Cytotechnology       Date:  2009-02-12       Impact factor: 2.058

8.  Stable high-producer cell clone expressing virus-like particles of the Japanese encephalitis virus e protein for a second-generation subunit vaccine.

Authors:  Asato Kojima; Atsushi Yasuda; Hideki Asanuma; Toyokazu Ishikawa; Akihisa Takamizawa; Kotaro Yasui; Takeshi Kurata
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

9.  The Murray Valley encephalitis virus prM protein confers acid resistance to virus particles and alters the expression of epitopes within the R2 domain of E glycoprotein.

Authors:  F Guirakhoo; R A Bolin; J T Roehrig
Journal:  Virology       Date:  1992-12       Impact factor: 3.616

10.  Major antigenic region on the integrase (IN) protein of human immunodeficiency virus type 1 determined by reactivity of human sera and a monoclonal antibody to IN protein.

Authors:  Y Tachibana; A Yasuda; T Kurata; S Oka; K Shimada; A Kojima
Journal:  Clin Diagn Lab Immunol       Date:  1994-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.